Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results

Posted by Kyle Jackson on May 14th, 2026

Artelo Biosciences (NASDAQ:ARTL – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($4.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($3.22), FiscalAI reports.

Artelo Biosciences Stock Up 1.3%

Shares of ARTL stock traded up $0.03 during mid-day trading on Thursday, reaching $2.34. The company’s stock had a trading volume of 84,081 shares, compared to its average volume of 2,318,749. The company’s 50 day simple moving average is $4.94 and its 200-day simple moving average is $5.10. Artelo Biosciences has a 12-month low of $2.30 and a 12-month high of $85.80. The firm has a market capitalization of $2.19 million, a PE ratio of -0.04 and a beta of 0.05.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ARTL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, April 25th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Artelo Biosciences has a consensus rating of “Reduce” and an average price target of $54.00.

Check Out Our Latest Stock Analysis on ARTL

Artelo Biosciences Company Profile

(Get Free Report)

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.